Sachet A. Shukla
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sachet A. Shukla has a total of 663 co-authors. Here are the top co-authors by number of shared publications:
- Catherine J. Wu
Dana-Farber Cancer Institute
66 shared publications Bo Li
34 shared publications- Toni K. Choueiri
Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
29 shared publications - David A. Braun
Yale School of Medicine, New Haven, CT, USA
27 shared publications - Sabina Signoretti
Harvard Medical School, Boston, USA
25 shared publications Catherine J. Wu
22 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Data from Proteogenomic Profiling Identifies FGFR2b as a Prevalent Cell Surface Target in Intrahepatic Cholangiocarcinoma
Purpose:Intrahepatic cholangiocarcinoma (iCCA) is increasing in incidence and is associated with limited treatment options and poor prognosis, particularly in advanced disease. Recently, biologic strategies such as antibody–drug conjugates have expanded therapeutic opportunities across many tumor types, including HER2/neu-altered iCCA. However, validated and prevalent cell surface targets suitable for biologic therapies remain uncommon in iCCA, representing a critical bottleneck to the development of novel targeted treatments. In particular, gene-level analyses overlook tumor-enriched protein isoforms produced through alternative splicing. Experimental Design:To address this gap, we applied a novel isoform-resolved proteogenomic approach comprising transcriptomics, in silico translation, and cell surfaceomics to identify prevalent cell surface targets in iCCA and further assessed their specificity through analysis of expression data from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression datasets. Results:This approach identified a unique peptide corresponding to fibroblast growth factor receptor 2b (FGFR2b), a splicing isoform of FGFR2, that demonstrated markedly higher tumor enrichment than the alternative FGFR2 isoform, FGFR2c. FGFR2b was the predominant FGFR2 isoform in biliary tract cancer, including iCCA, in both our institutional cohort (88.6%) and TCGA (88.2%). FGFR2 fusions, in particular, were associated with high FGFR2b expression. High FGFR2b expression was associated with improved surgical outcomes, epithelial differentiation, and reduced CD8+ T-cell infiltration. Orthogonal validation using IHC in a subset of 20 patients with available tissue samples confirmed membrane-bound FGFR2b expression in 31.6% of iCCA cases, including all patients with FGFR2 fusions. Conclusions:Our findings identify FGFR2b as a prevalent and compelling therapeutic target in iCCA and provide a strong rationale for ongoing and future FGFR2b-targeted clinical trials.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Proteogenomic Profiling Identifies FGFR2b as a Prevalent Cell Surface Target in Intrahepatic Cholangiocarcinoma
Purpose:Intrahepatic cholangiocarcinoma (iCCA) is increasing in incidence and is associated with limited treatment options and poor prognosis, particularly in advanced disease. Recently, biologic strategies such as antibody–drug conjugates have expanded therapeutic opportunities across many tumor types, including HER2/neu-altered iCCA. However, validated and prevalent cell surface targets suitable for biologic therapies remain uncommon in iCCA, representing a critical bottleneck to the development of novel targeted treatments. In particular, gene-level analyses overlook tumor-enriched protein isoforms produced through alternative splicing. Experimental Design:To address this gap, we applied a novel isoform-resolved proteogenomic approach comprising transcriptomics, in silico translation, and cell surfaceomics to identify prevalent cell surface targets in iCCA and further assessed their specificity through analysis of expression data from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression datasets. Results:This approach identified a unique peptide corresponding to fibroblast growth factor receptor 2b (FGFR2b), a splicing isoform of FGFR2, that demonstrated markedly higher tumor enrichment than the alternative FGFR2 isoform, FGFR2c. FGFR2b was the predominant FGFR2 isoform in biliary tract cancer, including iCCA, in both our institutional cohort (88.6%) and TCGA (88.2%). FGFR2 fusions, in particular, were associated with high FGFR2b expression. High FGFR2b expression was associated with improved surgical outcomes, epithelial differentiation, and reduced CD8+ T-cell infiltration. Orthogonal validation using IHC in a subset of 20 patients with available tissue samples confirmed membrane-bound FGFR2b expression in 31.6% of iCCA cases, including all patients with FGFR2 fusions. Conclusions:Our findings identify FGFR2b as a prevalent and compelling therapeutic target in iCCA and provide a strong rationale for ongoing and future FGFR2b-targeted clinical trials.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables1 from Proteogenomic Profiling Identifies FGFR2b as a Prevalent Cell Surface Target in Intrahepatic Cholangiocarcinoma
Supplementary Tables1 from Proteogenomic Profiling Identifies FGFR2b as a Prevalent Cell Surface Target in Intrahepatic Cholangiocarcinoma
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables1 from Proteogenomic Profiling Identifies FGFR2b as a Prevalent Cell Surface Target in Intrahepatic Cholangiocarcinoma
Supplementary Tables1 from Proteogenomic Profiling Identifies FGFR2b as a Prevalent Cell Surface Target in Intrahepatic Cholangiocarcinoma
- 18 August 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (21) , 4945-4955
Proteogenomic Profiling Identifies FGFR2b as a Prevalent Cell Surface Target in Intrahepatic Cholangiocarcinoma
Purpose: Intrahepatic cholangiocarcinoma (iCCA) is increasing in incidence and is associated with limited treatment options and poor prognosis, particularly in advanced disease. Recently, biologic strategies such as antibody–drug conjugates have expanded therapeutic opportunities across many tumor types, including HER2/neu-altered iCCA. However, validated and prevalent cell surface targets suitable for biologic therapies remain uncommon in iCCA, representing a critical bottleneck to the development of novel targeted treatments. In particular, gene-level analyses overlook tumor-enriched protein isoforms produced through alternative splicing. Experimental Design: To address this gap, we applied a novel isoform-resolved proteogenomic approach comprising transcriptomics, in silico translation, and cell surfaceomics to identify prevalent cell surface targets in iCCA and further assessed their specificity through analysis of expression data from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression datasets. Results: This approach identified a unique peptide corresponding to fibroblast growth factor receptor 2b (FGFR2b), a splicing isoform of FGFR2, that demonstrated markedly higher tumor enrichment than the alternative FGFR2 isoform, FGFR2c. FGFR2b was the predominant FGFR2 isoform in biliary tract cancer, including iCCA, in both our institutional cohort (88.6%) and TCGA (88.2%). FGFR2 fusions, in particular, were associated with high FGFR2b expression. High FGFR2b expression was associated with improved surgical outcomes, epithelial differentiation, and reduced CD8+ T-cell infiltration. Orthogonal validation using IHC in a subset of 20 patients with available tissue samples confirmed membrane-bound FGFR2b expression in 31.6% of iCCA cases, including all patients with FGFR2 fusions. Conclusions: Our findings identify FGFR2b as a prevalent and compelling therapeutic target in iCCA and provide a strong rationale for ongoing and future FGFR2b-targeted clinical trials.
- 18 August 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (21) , 4945-4955
Proteogenomic Profiling Identifies FGFR2b as a Prevalent Cell Surface Target in Intrahepatic Cholangiocarcinoma
Purpose: Intrahepatic cholangiocarcinoma (iCCA) is increasing in incidence and is associated with limited treatment options and poor prognosis, particularly in advanced disease. Recently, biologic strategies such as antibody–drug conjugates have expanded therapeutic opportunities across many tumor types, including HER2/neu-altered iCCA. However, validated and prevalent cell surface targets suitable for biologic therapies remain uncommon in iCCA, representing a critical bottleneck to the development of novel targeted treatments. In particular, gene-level analyses overlook tumor-enriched protein isoforms produced through alternative splicing. Experimental Design: To address this gap, we applied a novel isoform-resolved proteogenomic approach comprising transcriptomics, in silico translation, and cell surfaceomics to identify prevalent cell surface targets in iCCA and further assessed their specificity through analysis of expression data from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression datasets. Results: This approach identified a unique peptide corresponding to fibroblast growth factor receptor 2b (FGFR2b), a splicing isoform of FGFR2, that demonstrated markedly higher tumor enrichment than the alternative FGFR2 isoform, FGFR2c. FGFR2b was the predominant FGFR2 isoform in biliary tract cancer, including iCCA, in both our institutional cohort (88.6%) and TCGA (88.2%). FGFR2 fusions, in particular, were associated with high FGFR2b expression. High FGFR2b expression was associated with improved surgical outcomes, epithelial differentiation, and reduced CD8+ T-cell infiltration. Orthogonal validation using IHC in a subset of 20 patients with available tissue samples confirmed membrane-bound FGFR2b expression in 31.6% of iCCA cases, including all patients with FGFR2 fusions. Conclusions: Our findings identify FGFR2b as a prevalent and compelling therapeutic target in iCCA and provide a strong rationale for ongoing and future FGFR2b-targeted clinical trials.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
Effect of MS-553 on healthy immune cells.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
Effect of MS-553 on healthy immune cells.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S12 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
BTK mutant knock-in cell lines.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S12 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
BTK mutant knock-in cell lines.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
PKCβ is accessible and upregulated in dual-refractory CLL.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
PKCβ is accessible and upregulated in dual-refractory CLL.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
Effect of MS-553 on BCR Signaling.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
Effect of MS-553 on BCR Signaling.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
Effect of MS-553 on PKCβ and PKCε in CLL.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
Effect of MS-553 on PKCβ and PKCε in CLL.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
Effect of MS-553 on Wnt/β-catenin signaling.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
Effect of MS-553 on Wnt/β-catenin signaling.